title: Preventive effects of sulphasalazine on colorectal carcinogenesis in mice with ulcerative colitis.
abstract: Sulphasalazine has been used in the treatment of ulcerative colitis and is known to be a prodrug and split into sulphapyridine and 5-aminosalicylic acid by bacteria in the colon. An increased incidence of colorectal carcinoma is known to occur in patients with ulcerative colitis, which displays a recurrence-remission cycle on colorectal mucosa, i.e., the ulceration and regeneration periods of the colorectal mucosa. Repeated mucosal necrosis-regeneration sequence in chronic ulcerative colitis induced with 3% dextran sulfate sodium led to colorectal carcinogenesis in azoxymethane-pretreated mice. Additive treatment with sulphasalazine normalized the enlarged organs, i.e. liver, spleen and kidney and anemia and leucocytosis induced with 3% dextran sulfate sodium resulted in the reduction of tumorous regions with high-grade dysplasia.
authors.affiliation: School of Medical Technology, Bunkyo Jogakuin, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Suzuki
authors.forename: S
authors.initials: S
authors.lastname: Sakamoto
authors.forename: T
authors.initials: T
authors.lastname: Mitamura
authors.forename: S
authors.initials: S
authors.lastname: Sassa
authors.forename: H
authors.initials: H
authors.lastname: Kudo
authors.forename: Y
authors.initials: Y
authors.lastname: Yamashita
mesh_terms: D000818:Animals; D001835:Body Weight; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D015179:Colorectal Neoplasms / Q000517:prevention & control*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D051379:Mice; D008808:Mice, Inbred CBA; D009929:Organ Size; D012460:Sulfasalazine / Q000627:therapeutic use*
chemical_list: D005765:Gastrointestinal Agents; D012460:Sulfasalazine